• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can Sildenafil Citrate Help in the Management of Oligohydramnios?

image_pdfFavoriteLoadingFavorite

PURPOSE:

Sildenafil citrate is a well-known medication used to treat erectile dysfunction and pulmonary arterial hypertension, with positive impact on blood flow. This study by Maher et al. (Obstetrics and Gynecology, 2017) aimed to determine if sildenafil citrate, in combination with hydration, improves the amniotic fluid index (AFI) and neonatal outcomes in pregnancies with idiopathic oligohydramnios.

METHODS:

Randomized Controlled Trial

RESULTS:

184 women with singleton pregnancies, ≥ 30 weeks gestation and AFI < 5 cm were either given 25mg of sildenafil citrate every 8 hours and 2L isotonic fluids (treatment) or only the fluids (control) until delivery. Initial treatment was provided in hospital, with IV fluids run at 250 mL/h, and once discharged, patients were asked to take 2 L of fluid orally per day. Primary study outcome was AFI at 6 weeks of follow up or AFI at delivery (depending on what occurred first). 166 of the women completed the follow up (treatment group n=82, control group n=84). AFI at the final assessment was 11.5 cm in the treatment group vs. 5.4 cm in the control group (P=0.02). The sildenafil citrate / hydration group delivered later than those who only received hydration only (38.3 weeks vs. 36 weeks; P=0.001). In addition, C-section rates were lower (28% vs. 73%; P=.001). NICU admissions were likewise reduced (11% vs. 41%; P=0.001). Other statistically significant outcomes that were improved in the treatment arm included umbilical artery pH < 7.2 (P=0.016) and 5-min Apgar scores < 7 (P=0.001). The authors do point out limitations of the study, including lack of placebo, maternal positioning and relationship to AFI was not assessed and AFI, but not actual amniotic fluid volume was analyzed. Nevertheless, the investigators conclude that sildenafil citrate may provide another option to improve pregnancy outcomes complicated by oligohydramios.

Learn More – Primary Sources:

Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Deepest Pocket or AFI When Performing Prenatal Ultrasound?  

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site